secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001564590-22-020177
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics expands at-the-market equity facility by $50M to $62M total
------------------------------------------------------------------------------

- Amended Sales Agreement with SVB Securities to increase max aggregate offering from $12M to $62M, adding $50M in capacity.
- Shares sold in ATM offerings under Rule 415; SVB receives 3.0% commission on gross proceeds.
- Company will file a prospectus supplement under existing shelf registration statement (File No. 333-239499).
- No obligation to sell; either party may suspend the offering at any time.
- SVB affiliate Silicon Valley Bank is lender under a separate $14M term loan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022020177/0001564590-22-020177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022020177/trvi-8k_20220513.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-020177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer